Milk thistle extracts have been used as traditional herbal remedies for almost 2000 years. The extracts are still widely used to protect the liver against toxins and to control chronic liver diseases. Recent experimental and clinical studies suggest that milk thistle extracts also have anticancer, antidiabetic, and cardioprotective effects. This article reviews clinical trials of milk thistle conducted in the past 5 years including pharmacokinetic and toxicity studies, herb-drug interactions, and other safety issues. Several trials have studied the effects of milk thistle for patients with liver diseases, cancer, hepatitis C, HIV, diabetes, and hypercholesterolemia. Promising results have been reported in the protective effect of milk thistle in certain types of cancer, and ongoing trials will provide more evidence about this effect. In addition, new established doses and improvement on the quality and standardization of this herb will provide the much-awaited evidence about the efficacy of milk thistle in the treatment of liver diseases. Milk thistle extracts are known to be safe and well tolerated, and toxic or adverse effects observed in the reviewed clinical trials seem to be minimal. The future of milk thistle research is promising, and high-quality randomized clinical trials on milk thistle versus placebo may be needed to further demonstrate the safety and efficacy of this herb.
Crocenzi FA , Roma MGSilymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication . Cure Med Chem.2006;13: 1055-1074 .
2.
Rambaldi A. , Jacobs BP , Iaquinto G. , Gluud C.Milk thistle for alcoholic and/or hepatitis b or c liver diseases—a systematic Cochrane Hepato-Biliary Group review with meta-analyses of randomized clinical trials . Am J Gastroenterol.2005;100: 2583-2591 .
3.
Rambaldi A. , Jacobs BP , Iaquinto G. , Gluud C.Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases . Cochrane Database Syst Rev.2005; (2): CD003620.
4.
Mayer KE , Myers RP , Lee SSSilymarin treatment of viral hepatitis: a systematic review . J Viral Hepat. 2005;12: 559-567 .
5.
Kidd P. , Head K.A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (siliphos) . Altern Med Rev. 2005;10(3): 193-203 .
6.
Ladas E. , Kelly K.Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? J Alt CompMed.2003; 9(3): 411-416 .
7.
Mulrow C. , Lawrence V. , Jacobs B. , et al. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects . Evidence Report Technology Assessment (Summary)2000:21: 1-3 . Evidence Report/Technology Assessment no. 21. Rockville, Md: Agency for Healthcare Research and Quality ; 2000. 01-E024 . Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.29128 . Accessed December 12, 2006.
8.
Jacobs BP , Dennehy C. , Ramirez G. , Sapp J. , Lawrence VAMilk thistle for the treatment of liver disease: a systematic review and meta-analysis . Am J Med.2002;113(6): 506-515 .
9.
Saller R. , Meier R. , Brignoli R.The use of silymarin in the treatment of liver diseases . Drugs. 2000;61: 2035-2063 .
10.
Tyagi AK , Agarwal C. , Chan DC , Agarwal R.Synergistic anticancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells . Oncol Rep. 2004; 11 (2): 493-499 .
11.
von Schonfeld J. , Weisbrod B. , Muller MKSilibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity . Cell Mol Life Sci.1997;53 (11-12): 917-920 .
12.
Sridar C. , Goosen TC , Kent UM , et al. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases . Drug Metab Dispos.2004; 32(6): 587-594 .
13.
Milk thistle (Silybum marianum). In: Coates P , Blackman M , Cragg G , et al, eds. Encyclopedia of Dietary Supplements . New York: Marcel Dekker ; 2005:467-482.
14.
Natural Standard Database.Milk thistle (Silybum marianum), silymarin. Available at: http://www.naturalstandard.com . Accessed December 12, 2006.
15.
Gurley BJ , Barone GW , Williams DK , et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans . Drug Metab Dispos.2006; 34(1): 69-74 .
16.
Piscitelli SC , Formentini E. , Burstein AH , et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers . Pharmacotherapy. 2002;22(5): 551-556 .
17.
DiCenzo R. , Shelton M. , Jordan K. , et al. Coadministration of milk thistle and indinavir in healthy subjects . Pharmacotherapy. 2003;23(7): 866-870 .
18.
Mills E. , Wilson K. , Clarke M. , et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis . Eur J Clin Pharmacol.2005;61 (1): 1-7 .
19.
Gurley B. , Hubbard MA , Williams DK , et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin . J Clin Pharmacol.2006;46(2): 201-213 .
20.
Boari C. , Montanari FM , Galletti GP , et al. Toxic occupational liver diseases. Therapeutic effects of silymarin [in Italian] . Minerva Med.1981;72(40): 2679-2688 .
21.
Parish RC , Doering PLTreatment of Amanita mushroom poisoning: a review . Vet Hum Toxicol.1986;28(4): 318-322 .
22.
Szilard S. , Szentgyorgyi D. , Demeter I.1988. Protective effect of Legalon in workers exposed to organic solvents . Acta Med Hung.1988;45(2): 249-256 .
23.
Palaciano G. , Portincasa P. , Palmier V. , et al. The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs . Curr Ther Res Clin Exp. 1994;55(5): 537-545 .
24.
Benda L. , Dittrich H. , Ferenzi P. , Frank H. , Wewalka F.1980. The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis (author's transl) [in German] . Wien Klin Wochenschr.1980;92(19): 678-683 .
25.
Hruby K. , Fuhrmann M. , Csomos G. , Thaler H.1983. Pharmacotherapy of Amanita phalloides poisoning using silybin [in German] . Wien Klin Wochenschr.1983;95(7): 225-231 .
26.
Carducci R. , Armellino MF , Volpe C. , et al. 1996. Silibinin and acute poisoning with Amanita phalloides [in Italian] . Minerva Anestesiol.1996;62(5): 187-193 .
27.
Floersheim GL , Weber O. , Tschumi P. , Ulbrich M.1982. Amanita phalloides poisoning: prognostic factors and therapeutic measures. Analysis of 205 cases [in German] . Schweiz Med Wochenschr.1982;112(34): 1164-1177 .
28.
Brinker F.Herb Contraindications and Drug Interactions. 3rd ed. Sandy, Ore: Eclectic Medical ; 2001.
Singh RP , Agarwal R.Flavonoid antioxidant silymarin and skin cancer . Antioxid Redox Signal. 2002;4(4): 655-663 .
31.
Katiyar SKSilymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects . Int J Oncol.2005;26(1): 169-176 .
32.
Hoh C. , Boocock D. , Marczylo T. , et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences . Clin Cancer Res.2006; 12(9): 2944-2950 .
33.
Agarwal R. , Agarwal C. , Ichikawa H. , Singh RP , Aggarwal BBAnticancer potential of silymarin: from bench to bed side . Anticancer Res.2006;26(6B): 4457-4498 .
34.
McCarthy MF. Potential utility of natural polyphenols for reversing fat-induced insulin resistance . Med Hypotheses.2005;64(3): 628-635 .
35.
Maghrani M. , Zeggwagh NA , Lemhadri A. , El Amraoui M. , Michel JB , Eddouks M.Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus . J Ethnopharmacol.2004;91 (2-3): 309-316 .
36.
Varghese L. , Agarwal C. , Tyagi A. , Singh RP , Agarwal R.Silibinin efficacy against human hepatocellular carcinoma . Clin Cancer Res.2005;11 (23): 8441-8448 .
37.
Bean P.The use of alternative medicine in the treatment of hepatitis C . Am Clin Lab. 2002:19-21.
38.
Ladas EJ , Cheng B. , Hughes D. , Blumberg J. , McArthur RB , Kelly KMMilk thistle (Silybum marianum) is associated with reductions in liver function tests (LFTs) in children undergoing therapy for acute lymphoblastic leukemia (ALL). Presented at the 3rd International Conference of the Society for Integrative Oncology; November 11, 2006; Boston, Mass. Abstract D045.
39.
Singh RP , Agarwal R.Prostate cancer prevention by silibinin. Curr Cancer DrugTargets. 2004;4: 1-11 .
40.
Gagnier JJ , Boon H. , Rochon P. , Moher D. , Barnes J. , Bombardier C.Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement . Ann Intern Med.2006;144: 364-367 .
41.
Gagnier JJ , Boon H. , Rochon P. , Moher D. , Barnes J. , Bombardier C.Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration . J Clin Epidemiol.2006;59: 1134-1149 .
42.
Ladas EJ , Kelly KMMilk thistle: is there a role for its use as an adjunct therapy in patients with cancer?J Altern Complement Med.2003 ;9(3): 411-416 .
43.
Jadad AR , Moore A. , Carrol D. , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary ? Control Clin Trials.1996;17: 1-12 .
44.
Flaig T. , Agarwal R. , Su LJ , Harrison GS , Gustafson DL , Glode LMA phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients . Invest New Drugs. 2007;25(2): 139-146 .
45.
Dietzmann J. , Thiel U. , Ansorge S. , Neumann KH , Tager M.Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy . Free Radic Biol Med.2002;33(10): 1347-1354 .
46.
Kim YC , Kim EJ , Lee ED , et al. Comparative bioavailability of silibinin in healthy male volunteers . Int J Clin Pharmacol Ther.2003;41 (12): 593-596 .
47.
van Erp Nph , Baker SD , Zhao M. , et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan . Clin Cancer Res.2005;11 (21): 7800-7806 .
48.
Gurley BJ , Gardner SF , Hubbard MA , et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto . Clin Pharmacol Ther.2004;76(5): 428-440 .
49.
Ladas EJ , Cheng B. , Hughes D. , et al. Milk thistle is associated with reductions in liver function tests in children undergoing therapy for acute lymphoblastic leukemia. Presented at the Annual Meeting of the American Society of Hematology ; December 8-11, 2006; Atlanta, Ga .
50.
Schroder FH , Roobol MJ , Boeve ER , et al. Randomized, double-lind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol.2005;48(6): 922-930 .
51.
Tanamly MD , Tadros F. , Labeeb S. , et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results . Dig Liver Dis. 2004;36(11): 752 .
52.
Strickland GT , Tanamly MD , Tadros F. , et al. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C . Dig Liver Dis. 2005;37(7): 542-543 .
53.
Gordon A. , Hobbs DA , Bowden DS , et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C . J Gastroenterol Hepatol.2006;21(1 Pt 2): 275-280 .
54.
El-Zayadi A-R. , Attia M. , Badran HM , et al. Non-interferon-based therapy: an option for amelioration of necroinflammation in hepatitis C patients who cannot afford interferon therapy . Liver Int. 2005:25(4): 746-751 .
55.
Torres M. , Rodriguez-Serrano F. , Rosario DJ , et al. Does Silybum marianum play a role in the treatment of chronic hepatitis C?P R Health Sci J. 2004;23(2 Suppl): 69-74 .
56.
Melhem A. , Stern M. , Shibolet O. , et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial . J Clin Gastroenterol.2005;39(8): 737-742 .
57.
Lucena MI , Andrade RJ , de la Cruz JP , et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study . Int J Clin Pharmacol Ther.2002;40(1): 2-8 .
58.
Lirussi F. , Beccarello A. , Zanette G. , et al. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent . Diabetes Nutr Metab.2002;15 (4): 222-231 .
59.
Huseini HF , Larijani B. , Heshmat R. , Fakhrzadeh H. , Radjabipour B.The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial . Phytother Res. 2006;20(12): 1036-1039 .
60.
Madisch A. , Melderis H. , Mayr G. , Sassin I. , Hotz J.A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study [in German] . Z Gastroenterol.2001;39(7): 511-517 .
61.
Rainone F.Milk thistle . Am Fam Phys.2005;72(7): 1285-1288 .
National Institutes of Health.Management of hepatitis C: 2002. Rockville, Md: National Institutes of Health ; 2002. Available at: http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=3416&nbr=2642 . Accessed January 2007.
64.
Cavalieri E. , Chakravarti D. , Guttenplan J. , et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention . Biochim Biophys Acta.2006;1766(1): 63-78 .
